The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism and Other Factors on Tacrolimus Blood Concentration

• Conditions: Liver Transplantation; Kidney Transplantation
• Interventions: Other: Clinical and genetic factors

• Registration Number: NCT02707822
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The purpose of the study is to identify factors that may influence tacrolimus (TAC) pharmacokinetics, and the impact of gene polymorphism (ABCB1, CYP3A4, CYP3A5, POR) on pharmacokinetics of TAC in Taiwanese.

Detailed Description

TAC is one of the most important immunosuppressive agents for organ transplantation. In some patients the dose and concentration of TAC are difficult to adjust because of its narrow therapeutic index and variable pharmacokinetics.

Many factors affect the pharmacokinetics of TAC. Literature suggests that ABCB1, CYP3A4, CYP3A5, POR gene polymorphisms may affect the pharmacokinetics of TAC. In addition, the distribution of TAC is affected by hematocrit and albumin concentrations. The pharmacokinetics of TAC may also be affected by total protein, total bilirubin, creatinine, AST, ALT, gender, age, drug interactions, and so on.

This study intends to analyze the influence of various factors, including drugs, on the pharmacokinetics of TAC.

Study Timeline

• Study Start: 2016-01
• Status Verified: 2016-03
• Study First Submitted: 2016-03-09
• Study First Submitted QC: 2016-03-09
• Last Update Submitted: 2016-03-09
• Study First Posted: 2016-03-14
• Last Update Posted: 2016-03-14
• Primary Completion: 2018-12
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 440

Inclusion Criteria

• kidney transplants or liver transplants
• 20 - 65 years old
• receiving tacrolimus as immunosuppressive drugs

Exclusion Criteria

• Human immunodeficiency virus-positive status
• Retransplantation or multiorgan transplantation
• non-Asian

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
kidney or liver transplantation	Clinical and genetic factors	Renal or liver transplant recipients with tacrolimus as immunosuppressive drugs.

Primary Outcome Measures

Name	Time	Method
Dose-normalized tacrolimus concentration	Within the first 6 months post-transplantation

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan